Novartis Vijoice Gets Us Fda Accelerated Approval For Select Patients With Pik3Ca-Related Overgrowth Spectrum
Novartis Announced That The Us Food And Drug Administration (Fda) Granted Accelerated Approval To Vijoice (Alpelisib) For The Treatment Of Adult And Paediatric Patients 2 Years Of Age And Older With Severe Manifestations Of Pik3Ca-Related Overgrowth Spectrum (Pros) Who Require Systemic Therapy. Vijoice Is The First Fda-Approved Treatment For Pros, A Spectrum Of Rare Conditions Characterized By Overgrowths And Blood Vessel Anomalies Impacting An Estimated 14 People Per Million. In Accordance With The Accelerated Approval Programme, Continued Approval May Be Contingent Upon Verification And Description Of Clinical Benefit From Confirmatory Evidence.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
